Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
The Oncologist · 07.09.2023 · 28 (9) · 812-822
DOI: 10.1093/oncolo/oyad073 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 03.04.2023. Verfasst von Igor Stukalin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Melanoma, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Risk stratification tools for patients with advanced melanoma (AM) treated with immune checkpoint inhibitors (ICI) are lacking. We identified a new prognostic model associated with overall survival (OS). Patients and Methods A total of 318 treatment naïve patients with AM receiving ICI were collected from a multi-centre retrospective cohort study. LASSO Cox regression identified independent prognostic factors associated with OS. Model validation was carried out on 500 iterations of bootstrapped samples. Harrel’s C-index was calculated and internally validated to outline the model’s discriminatory performance. External validation was carried out in 142 advanced melanoma patients receiving ICI in later lines.
Results
High white blood cell count (WBC), high lactate dehydrogenase (LDH), low albumin, Eastern Cooperative Oncology Group (ECOG) performance status ≥1, and the presence of liver metastases were included in the model. Patients were parsed into 3 risk groups: favorable (0-1 factors) OS of 52.9 months, intermediate (2-3 factors) OS 13.0 months, and poor (≥4 factors) OS 2.7 months. The C-index of the model from the discovery cohort was 0.69. External validation in later-lines (N = 142) of therapy demonstrated a c-index of 0.65.
Conclusions
Liver metastases, low albumin, high LDH, high WBC, and ECOG≥1 can be combined into a prognostic model for AM patients treated with ICI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada.
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
ORCID-Profile: Igor Stukalin, Vishal Navani
Zitieren
APA
Stukalin, I., Navani, V., Gupta, M., Ruan, Y., Boyne, D. J., O'Sullivan, D. E., Meyers, D. E., Goutam, S., Sander, M., Ewanchuk, B. W., Brenner, D. R., Suo, A., Cheung, W. Y., Heng, D. Y. C., Monzon, J. G., & Cheng, T. (2023). Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. The Oncologist, 28(9), 812-822. https://doi.org/10.1093/oncolo/oyad073
Vancouver
Stukalin I, Navani V, Gupta M, Ruan Y, Boyne DJ, O'Sullivan DE, et al. Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. The Oncologist. 2023;28(9):812-822. doi:10.1093/oncolo/oyad073
BibTeX
@article{Stukalin2023,
author = {Stukalin, Igor and Navani, Vishal and Gupta, Mehul and Ruan, Yibing and Boyne, Devon J and O'Sullivan, Dylan E and Meyers, Daniel E and Goutam, Siddhartha and Sander, Michael and Ewanchuk, Benjamin W and Brenner, Darren R and Suo, Aleksi and Cheung, Winson Y and Heng, Daniel Y C and Monzon, Jose G and Cheng, Tina},
title = {Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {9},
pages = {812--822},
doi = {10.1093/oncolo/oyad073}
}
EUVIMED